| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -13.9 | -7.6 |
| Net income | -13.9 | -7.6 |
| EPS (diluted, $ a share) | $-0.19 | $-0.24 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: IMMX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Immix Biopharma, Inc.: key numbers
- Share price
- $7.20Close, Nov 17
- Market cap
- $603M
- Shares outstanding
- 83.81MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Immix Biopharma, Inc.
All →Immix Biopharma Business Update
Immix Biopharma reported its Q3 2026 operational progress, highlighting an 89% complete response rate in its NEXICART-2 clinical trial for NXC-201. The company strengthened its leadership team with new SVPs of Technical Operations and Regulatory Affairs as it prepares for a planned BLA submission in mid-2027.
Immix Biopharma Capital Raise of $125M
Immix Biopharma priced an underwritten public offering of 11,363,637 shares of common stock at $11.00 per share, generating gross proceeds of $125 million. The company intends to use the net proceeds to fund the development of its CAR-T cell therapy NXC-201, working capital, and general corporate purposes.
- Value
- $125M
- Counterparty
- J.P. Morgan Securities LLC
Immix Biopharma Clinical Trial Data
Immix Biopharma announced positive interim results from its Phase 2 NEXICART-2 clinical trial of NXC-201 in relapsed/refractory AL Amyloidosis, showing an 89% complete response rate across 45 patients. The company noted that MRD-negativity predicts future complete responses, potentially increasing the rate to 98%, and plans a BLA submission for the therapy in mid-2027.
- Earnings call
- Sep 29, 2026, 8:00 AM ET